Fresh from the biotech pipeline: FDA turmoil overshadows 2025 approvals
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
Nature Biotechnology, published online: January 19, 2026; doi:10.1038/s41587-025-02994-1
Leadership changes, staff reductions and a series of new policies have marked an agency in transition. New drug approvals included more follow-on products than first ones.
